Keytruda vs. Tagrisso

Are Keytruda and Tagrisso the Same Thing?

Keytruda (pembrolizumab) and Tagrisso (osimertinib) are anti-cancer drugs used to treat different types of cancers.

Keytruda is used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Tagrisso is used to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.

Keytruda is a monoclonal antibody and Tagrisso is a kinase inhibitor.

Side effects of Keytruda and Tagrisso that are similar include fatigue, cough, nausea, itching, rash, decreased appetite, headache, constipation, back pain, and diarrhea.

Side effects of Keytruda that are different from Tagrisso include shortness of breath, loss of skin pigmentation (vitiligo), and joint pain.

Side effects of Tagrisso that are different from Keytruda include dry skin, nail toxicity, inflammation of the mouth and lips, eye disorders, pneumonia, and blood clots.

Keytruda may interact with other drugs.

Tagrisso may interact with macrolide antibiotics, antifungals, antivirals, nefazodone, phenytoin, rifampicin, St. John's wWort, fentanyl, cyclosporine, quinidine, ergot alkaloids, and carbamazepine.

What Are Possible Side Effects of Keytruda?

Common side effects of Keytruda include:

Side effects of Keytruda include:

  • fatigue,
  • cough,
  • shortness of breath,
  • nausea,
  • itching,
  • rash,
  • loss of skin pigmentation (vitiligo),
  • decreased appetite,
  • headache,
  • constipation,
  • joint pain,
  • back pain, and
  • diarrhea.

What Are Possible Side Effects of Tagrisso?

Common side effects of Tagrisso include:

  • diarrhea,
  • rash,
  • dry skin,
  • nail toxicity,
  • nausea,
  • decreased appetite,
  • constipation,
  • inflammation of the mouth and lips,
  • itching,
  • eye disorders,
  • cough,
  • fatigue,
  • back pain,
  • headache,
  • pneumonia, and
  • blood clots.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

What Is Keytruda?

Keytruda (pembrolizumab) is a monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

What Is Tagrisso?

Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.

What Drugs Interact With Keytruda?

Keytruda may interact with other drugs. Tell your doctor all medications and supplements you use. Keytruda is not recommended for use during pregnancy; it may harm a fetus. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

What Drugs Interact With Tagrisso?

Tagrisso may interact with macrolide antibiotics, antifungals, antivirals, nefazodone, phenytoin, rifampicin, St. John's Wort, fentanyl, cyclosporine, quinidine, ergot alkaloids, and carbamazepine. Tell your doctor all medications and supplements you use. Tagrisso is not recommended for use during pregnancy; it may harm a fetus. Breastfeeding is not recommended during treatment with Tagrisso.

How Should Keytruda be Taken?

The recommended dose of Keytruda is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

How Should Tagrisso be Taken?

The dose of Tagrisso is 80 mg orally once daily, with or without food.

Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
Merck. Keytruda Product Information

https://www.keytruda.com/

AstraZeneca. Tagrisso Product Information.

https://www.tagrissohcp.com/

Health Solutions From Our Sponsors